FDA to unlock interim endpoints for accelerated approvals

FDA Commissioner Scott Gottlieb Thursday announced the agency’s intention to broaden the use of intermediate clinical endpoints to support accelerated approvals, teed up the agency’s release of new antibiotic drug development guidance and gave an early look at use of a new pathway for qualifying biomarkers. He also endorsed in principle proposals to create a new

Read the full 561 word article

User Sign In